Explore ViiV Healthcare

I am a

... looking for

US News

News
Company Statements

ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus TAF-containing regimens

08 Oct 2020
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1

05 Oct 2020
ViiV Healthcare presents a new podcast about the Power of Being Seen

01 Oct 2020
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

28 Sep 2020
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

28 Sep 2020
ViiV Healthcare Announces New Research Report “Here as I Am,” on Socio-Economic Forces Affecting Access to HIV Care for Latinx Gay and Bisexual Men

15 Sep 2020
ViiV Healthcare anuncia la publicación de su informe de investigación “Tal Como Soy”, que analiza las fuerzas socioeconómicas que afectan el acceso a servicios de salud de VIH para hombres latinxs gay y bisexuales

15 Sep 2020
ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1

20 Aug 2020
ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

06 Aug 2020
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

07 Jul 2020
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life

04 Jul 2020
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices

04 Jul 2020
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

02 Jul 2020
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

02 Jul 2020
ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic

30 Jun 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

12 Jun 2020
National AIDS Memorial and ViiV Healthcare Create Mary Bowman Arts in Activism Award to Support Young Artist-Activists Committed to the Fight Against HIV/AIDS

26 May 2020
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

18 May 2020
ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

27 Apr 2020
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting HIV-treatment regimen in adults living with HIV-1

09 Mar 2020
ViiV Healthcare presents positive, 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

09 Mar 2020
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

09 Mar 2020
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

02 Mar 2020
ViiV Healthcare submits regulatory application to the European Medicines Agency for investigational fostemsavir, a first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

10 Jan 2020

ViiV Healthcare COVID-19 Community Emergency Response Fund

27 Apr 2020
ViiV Healthcare ranks #1 company in the PatientView ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ survey

21 Apr 2020
ViiV Healthcare’s commitment to support AIDS2020 and key conferences during COVID-19 outbreak

30 Mar 2020
COVID-19 Guidance to Investigators

27 Mar 2020
Our Response to COVID-19

16 Mar 2020

Website images are not intended to imply that the models pictured have HIV.

©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.

Connect with us